In today’s world, successful therapeutic developers must not only generate clinical data to meet regulatory requirements for approval, they must also demonstrate the value of therapeutic candidates to payers and, if asset partnership is a value-creating strategy, potential partners. In this panel, experts will outline key payer requirements for new therapies as well as criteria used by commercial pharma and biotech companies when evaluating potential assets for acquisition. The panelists will provide advice on designing clinical studies that can yield data that supports partnership and reimbursement negotiations. Finally, the challenge of paying for clinical studies that can generate data that maximize the chance of commercial or partnership success will be addressed, with a discussion of strategies companies can use to bridge the funding gap during clinical development.